Month: August 2024

Total Second Quarter Revenue of $29.2 Millionillumin Self-Service Revenue up 61% YoY and Represents 30% of Total RevenueAdjusted EBITDA Improvement of 11% YoY (All monetary figures are expressed in Canadian dollars unless otherwise stated) TORONTO, Aug. 08, 2024 (GLOBE NEWSWIRE) — illumin Holdings Inc. (TSX: ILLM) (OTCQB: ILLMF) (“illumin” or “Company”), a journey advertising technology company that empowers marketers to make smarter decisions about communicating with online consumers, today announced its financial results for the second quarter ended June 30, 2024. Second Quarter 2024 HighlightsSecond quarter 2024 revenue was $29.2 million compared to $33.2 million in Q2 2023, reflecting a decline in managed service revenue and programmatic revenue, primarily in Latin America. illumin self-serve revenue was $8.8 million in...

– Proof-of-Concept Phase 2 SHINE Trial Demonstrates ~40% Mean Improvement in ADAS-Cog 11 vs Placebo and Consistent Positive Changes Across Multiple Cognitive and Functional Measures – – On Track to Report Topline Results from SHIMMER Study in Mild-to-Moderate DLB by YE 2024 – – Company to Host Investor Conference Call at 8:30 a.m. – PURCHASE, N.Y., Aug. 08, 2024 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), today reported financial results for the second quarter ended June 30, 2024, and provided a business update. “We announced favorable results from the Phase 2 ‘SHINE’ Study that provided proof-of-concept that CT1812 has potential to slow the progression...

WINCHESTER, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) — Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the second quarter 2024 and provided a corporate update. In March 2024, the Company retained Lucid Capital Markets, LLC to act as its financial advisor to explore and evaluate strategic options for maximizing shareholder value. Potential strategic alternatives that may be explored or evaluated as part of this process include the potential for an acquisition, merger, business combination or other strategic transaction involving the Company. The Board has not set a timetable for the conclusion of this review, nor has it made any decisions related to any further actions or potential strategic options at this time....

All amounts in U.S. dollars unless otherwise stated TORONTO, Aug. 08, 2024 (GLOBE NEWSWIRE) — Onex Corporation (TSX: ONEX) today announced its financial results for the second quarter and six months ended June 30, 2024. “We made solid progress in the quarter including growth in investing capital per share, raising new capital across our platforms and crystallizing attractive returns through realization activity,” said Bobby Le Blanc, CEO and President of Onex. “We remain focused on areas where we have the right to compete and intend to allocate our capital and resources to opportunities with the greatest potential to drive long-term shareholder value.”Financial Results ($ millions except per share amounts)Three Months Ended June 30  Six Months Ended June 30  2024 2023 2024 2023Net earnings (loss) $ 168   $ 132   $ 178   $ (100 )Net...

Q2 2024 Total Revenue of $126.7M, a 34% Increase Year-over-Year Galafold® Q2 Revenue of $110.8M, up 17% Year-over-Year Pombiliti® + Opfolda® Q2 Revenue of $15.9M, up 44% from Q1 2024 Raising 2024 Total Revenue Growth Guidance to 26%-31% at CER and 2024 Galafold Growth Guidance to 14%-18% at CER Narrowing non-GAAP Operating Expense Guidance to $345M to $360M Non-GAAP Profitability Achieved in Q2 and H1 2024 with Acceleration Expected in H2 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) —  Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced financial results for the second quarter ended June 30, 2024. “In the first half of 2024 we demonstrated strong commercial...

Phase 2 study of NTLA-2002 for hereditary angioedema (HAE) met its primary and all secondary endpoints; plan to present detailed results at an upcoming medical meeting in the fourth quarter Selected the 50 mg dose of NTLA-2002 for the pivotal Phase 3 trial on track to begin in 2H 2024 Rapid enrollment continues in the Phase 3 MAGNITUDE trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy On track to initiate the Phase 3 study of NTLA-2001 for the treatment of hereditary ATTR amyloidosis with polyneuropathy by year-end Plan to present new clinical data from the ongoing NTLA-2001 Phase 1 in 2H 2024 Expect to dose the first patient in the Phase 1/2 study of NTLA-3001, an in vivo gene insertion candidate for the treatment of alpha-1 antitrypsin deficiency (AATD) in 2H 2024 Ended the second quarter...